VCP Scanner
ScreenerTechnicalBreakoutsThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistPricing
ScreenerTechnical ScannerBreakoutsThemes
Earnings
WatchlistPricing
Ctrl K
JBS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
JBSJbs N.V.
$13.44$29.8B
Overview & Verdict
OverviewVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksJBSBalance Sheet

Jbs N.V. (JBS) Balance Sheet

12Y historyFree accessUpdated daily

Leverage remains elevated with debt-to-equity at 2.55 and total debt of $119.3B, while retained earnings plummeted 90% to $1.1B in 2026Q1, signaling deteriorating equity quality and a thinner liquidity buffer as cash fell to $17.0B.

JBS Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14
Total Current Assets17.76B101.4B655.62B386.36B79.39B83.91B60.54B41.92B36.9B36.11B33.92B49.81B37.54B
Cash & Short-Term Investments3.47B25.98B214.97B108.74B13.18B23.24B19.68B10.03B8.94B11.74B9.36B18.84B14.91B
Cash Only3.47B25.11B214.97B108.74B13.18B23.24B19.68B10.03B8.94B11.74B9.36B18.84B8.37B
Short-Term Investments0877.53M00000000006.54B
Accounts Receivable3.56B29.4B143.05B80.69B20.23B19.88B14B11.14B9.66B9.33B9.59B12.12B9.58B
Days Sales Outstanding19.822.78125.2280.9519.2420.0118.9119.8719.420.8820.5427.1529.02
Inventory7B43.63B253.66B162.13B37.85B33.95B22.7B17.35B14.5B12.45B12.28B13.98B9.84B
Days Inventory Outstanding37.938.77261.41182.5542.7842.1536.8336.6934.0832.630.0736.3735.29
Other Current Assets3.74B2.38B43.94B34.8B8.12B6.85B4.15B3.41B3.8B2.58B2.69B4.86B3.03B
Total Non-Current Assets28.08B146.94B902.35B626.82B128.72B123.34B103.26B84.42B77.25B72.59B68.9B72.69B44.5B
Property, Plant & Equipment16.04B62.58B532.12B360.63B73.16B67.05B54.74B44.06B36.28B34.53B34.09B36.48B24.73B
Fixed Asset Turnover7.00x7.53x0.78x1.01x5.25x5.41x4.94x4.64x5.01x4.73x5.00x4.47x4.87x
Goodwill5.98B32.19B207.44B145.27B30.41B32.56B28.89B24.5B23.78B22.49B21.92B24.41B12.99B
Intangible Assets1.78B10.04B69.05B47.25B10.33B12B7.82B6.05B5.82B5.51B5.01B6.89B2.45B
Long-Term Investments53.77B26.13B1.47B1.35B294.84M243.19M171.1M93.63M84.97M64.01M362.63M354.13M295.35M
Other Non-Current Assets3.34B13B92.28B72.31B14.52B11.48B11.65B9.71B11.29B10B7.52B4.55B4.04B
Total Assets45.84B248.34B1.56T1.01T208.11B207.25B163.8B126.34B114.15B108.7B102.82B122.5B82.04B
Asset Turnover2.00x1.90x0.27x0.36x1.85x1.75x1.65x1.62x1.59x1.50x1.66x1.33x1.47x
Asset Growth %-80.03%-84.06%53.77%386.84%0.41%26.53%29.65%10.68%5.01%5.72%-16.07%49.31%-
Total Current Liabilities11.58B63.48B446.39B235.51B55.16B59.81B40.84B28.46B21.6B29.18B33.35B40.14B24.87B
Accounts Payable5.85B40.33B209.29B125.1B31.01B30.22B22.2B15.44B12.17B9.99B10.72B12.42B6.94B
Days Payables Outstanding31.2635.83215.69140.8535.0537.5136.0132.6528.5826.1726.2432.3124.89
Short-Term Debt13.08B6.53B107.72B43.78B11.3B14.6B6.66B4.09B3.83B13.53B18.15B20.91B13.69B
Deferred Revenue (Current)378.94M000000000000
Other Current Liabilities-9.95B6.45B57.19B23.95B4.09B5.66B4.33B3.37B1.57B2.17B1.46B3.55B2.13B
Current Ratio1.53x1.60x1.47x1.64x1.44x1.40x1.48x1.47x1.71x1.24x1.02x1.24x1.51x
Quick Ratio0.93x0.91x0.90x0.95x0.75x0.84x0.93x0.86x1.04x0.81x0.65x0.89x1.11x
Cash Conversion Cycle26.4425.72170.95122.6526.9724.6519.7323.9124.8927.3224.3731.2239.41
Total Non-Current Liabilities130.26B132.5B800.1B546.66B103.14B99.65B79.42B65.4B64.6B53.38B45.95B52.74B31.53B
Long-Term Debt110.19B111.41B660.27B454.68B84.13B80.6B61.34B50.95B53.23B43.5B38.11B44.98B26.39B
Capital Lease Obligations30.13B7.77B53.55B35.42B7.2B6.78B4.81B3.77B00000
Deferred Tax Liabilities18.34B6.43B00000000000
Other Non-Current Liabilities12.69B6.89B86.28B56.56B11.82B12.26B13.27B10.68B11.37B9.88B7.84B7.77B5.14B
Total Liabilities36.78B195.97B1.25T782.17B158.3B159.45B120.26B93.86B86.2B82.56B79.3B92.88B56.4B
Total Debt1.79B125.71B834.39B542.27B104.41B103.61B74.11B59.75B57.06B57.02B56.26B65.88B40.08B
Net Debt-1.67B100.6B619.43B433.53B91.23B80.37B54.43B49.72B48.13B45.28B46.9B47.04B31.71B
Debt / Equity0.20x2.40x2.68x2.35x2.10x2.17x1.70x1.84x2.04x2.18x2.39x2.22x1.56x
Debt / EBITDA0.07x3.57x24.94x38.57x2.95x2.43x2.76x3.22x4.78x5.10x5.09x5.15x3.73x
Net Debt / EBITDA-0.06x2.85x18.51x30.83x2.58x1.88x2.03x2.68x4.03x4.05x4.24x3.68x2.95x
Interest Coverage2.66x2.57x15.60x3.44x19.28x34.51x5.65x3.24x2.01x1.49x2.12x3.71x2.99x
Total Equity9.06B52.37B311.49B231B49.81B47.8B43.54B32.48B27.95B26.14B23.52B29.62B25.64B
Equity Growth %-81.3%-83.19%34.84%363.78%4.21%9.77%34.06%16.23%6.91%11.16%-20.61%15.52%-
Book Value per Share8.8749.01140.43104.1422.0919.2816.4012.1810.489.198.6010.228.90
Total Shareholders' Equity42.52B47.87B276.92B213.08B46.34B44.12B40.12B29.64B25.65B24.29B22.37B28.03B23.87B
Common Stock214.85M171.18M145.8B115.88B23.58B23.58B23.58B23.58B23.58B23.58B23.58B23.58B21.51B
Retained Earnings5.86B11.5B113.46B75.59B18.65B13.49B7.17B5.22B2.49B2.28B3.65B4.76B4.26B
Treasury Stock-2.82B-3.25B000-3.04B-303.56M-605.72M-624.14M0-1.63B-903.57M-451.7M
Accumulated OCI1.5B39.44B16.36B20.56B3.9B9.88B9.47B1.23B-10.39M-1.78B-3.44B387.79M-1.66B
Minority Interest834.76M4.51B34.57B17.93B3.46B3.68B3.42B2.85B2.3B1.85B1.14B1.59B1.77B

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrained
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

High leverage and margin compression

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-Q (2026Q1)

Balance Sheet Contraction Amidst Cyclical Pressures

Total assets fell 6.2% from $248.3B in 2025Q4 to $232.9B in 2026Q1, while equity dropped 11.5% to $42.4B, as per reported figures, signaling a weakening balance sheet.

The sequential decline in total assets and equity suggests that the company is absorbing significant operational losses or impairments, consistent with the prior income statement showing a 54% drop in operating income. The reduction in retained earnings from $11.5B to $1.1B in one quarter indicates a substantial charge, possibly related to asset write-downs or dividend distributions, which warrants further investigation. This trajectory implies that the balance sheet is contracting, potentially limiting future financial flexibility.

Leverage Elevated as Debt Persists

Debt-to-equity rose to 2.55 in 2026Q1 from 2.40 in 2025Q4, with total debt at $119.3B, as per financial statements, indicating increased financial risk.

Despite a slight reduction in absolute debt from $125.7B to $119.3B, the equity base contracted faster, pushing leverage higher. The D/E ratio of 2.55 is significantly above peers like Tyson (0.48) and Hormel (0.36), suggesting that JBS is more vulnerable to interest rate fluctuations and refinancing risks. The high debt load may constrain capital allocation and increase interest expense, which could further pressure margins in a rising rate environment.

Asset Mix Reflects Heavy Tangible Base

PP&E net of $60.3B and goodwill of $30.8B together represent 39% of total assets in 2026Q1, as reported in SEC filings, indicating a capital-intensive model with significant intangible risk.

The substantial investment in PP&E underscores the asset-heavy nature of meat processing, while goodwill of $30.8B (13% of assets) exposes the balance sheet to potential impairment if acquired businesses underperform. The decline in PP&E from $62.6B to $60.3B sequentially may reflect depreciation or asset sales, but the high fixed asset base suggests ongoing maintenance capex needs. Investors should monitor goodwill for impairment triggers, especially given the recent margin compression.

Equity Quality Deteriorates on Retained Earnings Drop

Retained earnings plummeted from $11.5B in 2025Q4 to $1.1B in 2026Q1, a 90% decline, as per financial data, signaling a major hit to equity quality.

The sharp reduction in retained earnings likely reflects a combination of net losses, dividend payouts, or accounting adjustments, which erodes the equity buffer. This decline, coupled with a 11.5% drop in total equity, suggests that the company is not retaining sufficient earnings to support its asset base. The equity quality appears strained, which may limit the company's ability to absorb future shocks without further leveraging.

Liquidity Buffer Thins as Cash Declines

Cash fell from $25.1B in 2025Q4 to $17.0B in 2026Q1, while the current ratio dipped to 1.50, as reported in financial statements, indicating a reduced cushion against short-term obligations.

The $8.1B drop in cash is concerning given the company's high debt load and the negative operating cash flow of -$4.1B in the same quarter. The current ratio of 1.50, though above 1, is below the 1.60 seen in the prior quarter and suggests tightening liquidity. This reduced buffer may increase reliance on external financing, especially if working capital needs persist, as indicated by the prior cash flow analysis.

Hidden Risks in Biological Assets and Goodwill

Biological asset fair value changes and $30.8B goodwill may distort reported earnings, as per accounting disclosures, potentially masking underlying operational deterioration.

The balance sheet includes biological assets valued at fair value, which can introduce non-cash volatility into earnings, as noted in the company intelligence. Additionally, the large goodwill balance from past acquisitions may be at risk of impairment if the current margin compression persists, especially in the US beef segment. These factors could make the headline equity and asset figures misleading, and investors should adjust for these items when assessing the true financial health.

JBS — Frequently Asked Questions

Quick answers to the most common questions about buying JBS stock.

What are the total assets of Jbs N.V. (JBS)?

As of 2025, Jbs N.V. (JBS) had total assets of $248.34B including $101.40B in current assets.

How much debt does Jbs N.V. (JBS) have?

Jbs N.V. (JBS) carries total debt of $125.71B, offset by $25.98B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Jbs N.V.?

Jbs N.V. (JBS) has total shareholders' equity (book value) of $47.87B ($49.01 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Jbs N.V.'s current ratio and liquidity?

Jbs N.V. (JBS) reported a current ratio of 1.60x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.